Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1/2 5Phase 3 4Phase 1 4Phase 2/3 1

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Colorectal Neoplasms 93Stomach Neoplasms 56Rectal Neoplasms 51Colonic Neoplasms 47Pancreatic Neoplasms 20Neoplasms 14Carcinoma, Hepatocellular 14Neoplasm Metastasis 13Adenocarcinoma 10Parkinson Disease 4, Autosomal Dominant Lewy Body 9Lymphoma, Large B-Cell, Diffuse 9Cholangiocarcinoma 8Adenocarcinoma Of Esophagus 8Esophageal Neoplasms 5Biliary Tract Neoplasms 5Neurotoxicity Syndromes 4Esophageal Squamous Cell Carcinoma 4Lymphoma, Extranodal NK-T-Cell 3Gastrointestinal Neoplasms 3Gallbladder Neoplasms 3Peritoneal Neoplasms 2Lymphoma 2Liver Neoplasms 2Hepatoblastoma 2Gastrointestinal Diseases 2Colorectal Adenocarcinoma 2Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Spinocerebellar Degenerations 1

Interventions

Cisplatin 21Radiotherapy 16Fluorouracil 16Paclitaxel 14Irinotecan 7Docetaxel 7Neoadjuvant Therapy 6Drug Therapy 5tislelizumab 4sintilimab 4Surgical Procedures, Operative 4Radiation 4Oxaliplatin 4Leucovorin 4Esophagectomy 4Capecitabine 4toripalimab 3pembrolizumab 3TP protocol 3Chemotherapy, Adjuvant 3S 1 (combination) 2Levoleucovorin 2Cetuximab 2Carboplatin 2lenvatinib 1irinotecan sucrosofate 1durvalumab 1atropine sulfate-diphenoxylate hydrochloride drug combination 1atezolizumab 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Esophageal Squamous Cell Carcinoma × Oxaliplatin × Clear all
NCT04210115 2026-05-13

KEYNOTE 975

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
703 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT04949256 2025-12-15

MK-7902-014

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
864 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

NCT03783442 2025-07-29

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

BeiGene

Phase 3 Completed
649 enrolled 22 charts
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04460352 2025-03-06

NEEDS

Karolinska University Hospital

Phase 3 Recruiting
1,020 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡